Development and pharmacological assessment of novel peptide and nonpeptide oxytocin antagonists
- 29 April 1993
- journal article
- review article
- Published by Elsevier in Regulatory Peptides
- Vol. 45 (1-2) , 289-293
- https://doi.org/10.1016/0167-0115(93)90222-t
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Orally active, nonpeptide oxytocin antagonistsJournal of Medicinal Chemistry, 1992
- Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural productJournal of Medicinal Chemistry, 1992
- OPC-21268, an Orally Effective, Nonpeptide Vasopressin V1 Receptor AntagonistScience, 1991
- Bradykinin agonist activity of a novel, potent oxytocin antagonistEuropean Journal of Pharmacology, 1991
- Receptor ligands which bind the oxytocin receptor with selectivity and high affinity. Chemical modification of a Streptomyces silvensis derived cyclic hexapeptideJournal of Medicinal Chemistry, 1990
- Cyclic hexapeptide oxytocin antagonists. Potency-, selectivity-, and solubility-enhancing modificationsJournal of Medicinal Chemistry, 1990
- A Structurally Unique, Potent, and Selective Oxytocin Antagonist Derived from Streptomyces silvensisEndocrinology, 1989
- Inhibition of uterine contractions of premature labour with an oxytocin analogue. Results from a pilot studyBJOG: An International Journal of Obstetrics and Gynaecology, 1987
- Can primary dysmenorrhea be alleviated by a vasopressen antagonist?Acta Obstetricia et Gynecologica Scandinavica, 1987
- Endocrinology of human parturition: a reviewBJOG: An International Journal of Obstetrics and Gynaecology, 1984